> People could still pay for them out of pocket, but without the guarantee of insurance payments the drug companies likely won’t take the risk.
this, in my opinion, points out a significant flaw in the rush to privatize just about everything:
there are many many “markets” that are either under-served or not served at all because the rate of profit would be (a) too low to “justify” or (b)none at all.
jmo but, there has to be a balance between for-profit and basic research that won’t necessarily be able to be monetized to the extent many in industry would want...
this, in my opinion, points out a significant flaw in the rush to privatize just about everything:
there are many many “markets” that are either under-served or not served at all because the rate of profit would be (a) too low to “justify” or (b)none at all.
jmo but, there has to be a balance between for-profit and basic research that won’t necessarily be able to be monetized to the extent many in industry would want...